NMTC
NeuroOne Medical Technologies Corporation NASDAQ$4.35
Mkt Cap $29.1M
52w Low $3.28
29.2% of range
52w High $6.96
50d MA $4.57
200d MA $4.77
P/E (TTM)
-8.1x
EV/EBITDA
-9.8x
P/B
4.1x
Debt/Equity
0.0x
ROE
-106.7%
P/FCF
-12.2x
RSI (14)
—
ATR (14)
—
Beta
0.58
50d MA
$4.57
200d MA
$4.77
Avg Volume
40.5K
About
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, d…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -0.24 | -0.18 | +25.0% | 4.07 | +2.9% | +0.2% | +4.4% | +0.2% | +0.2% | +2.7% | +6.9% | — |
| Dec 17, 2025 | AMC | -0.04 | -0.05 | -25.0% | 4.01 | +0.0% | +7.2% | +10.0% | +20.2% | +7.2% | +14.5% | +35.2% | — |
| Aug 14, 2025 | AMC | -0.05 | -0.03 | +40.0% | 4.98 | -1.0% | -1.2% | +0.0% | -2.6% | -9.4% | -7.2% | +6.0% | — |
| May 13, 2025 | AMC | -0.09 | -0.07 | +22.2% | 3.86 | +1.0% | +2.6% | +2.1% | +3.4% | +2.8% | -3.4% | -10.9% | — |
| Feb 12, 2025 | AMC | -0.10 | 0.06 | +160.0% | 6.72 | +6.2% | +1.8% | +7.1% | +3.6% | +3.6% | +0.0% | -3.6% | — |
| Dec 17, 2024 | AMC | -0.09 | -0.11 | -22.2% | 4.74 | +3.6% | -6.3% | -4.0% | -4.0% | -6.1% | -2.5% | +31.6% | — |
| Aug 14, 2024 | AMC | -0.09 | -0.10 | -11.1% | 4.45 | -2.9% | -1.6% | -1.6% | +7.9% | +11.2% | +4.7% | +11.9% | — |
| May 14, 2024 | AMC | -0.09 | -0.11 | -22.2% | 6.84 | -2.6% | -7.0% | -7.9% | -5.3% | -7.9% | -8.8% | -16.5% | — |
| Feb 13, 2024 | AMC | -0.14 | -0.14 | +0.0% | 8.46 | -0.7% | -23.4% | -25.5% | -27.0% | -22.0% | -21.3% | -24.1% | — |
| Dec 14, 2023 | AMC | -0.17 | -0.13 | +25.7% | 10.32 | +0.0% | -11.0% | -20.9% | -18.6% | -19.8% | -19.2% | -25.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | Alliance Global Partners | Maintains | Buy → Buy | — | $6.54 | $6.54 | +0.0% | -3.7% | -7.3% | -6.4% | -7.3% | -5.5% |
| Mar 28 | Craig-Hallum | Downgrade | Buy → Hold | — | $13.32 | $10.50 | -21.2% | -46.8% | -47.3% | -49.5% | -50.5% | -51.4% |
| Dec 3 | Alliance Global Partners | Maintains | Buy → Buy | — | $12.54 | $12.90 | +2.9% | -1.9% | +8.1% | +14.8% | +20.6% | +24.4% |
| Nov 15 | Craig-Hallum | Maintains | Buy → Buy | — | $16.50 | $17.04 | +3.3% | -2.5% | -4.4% | -7.3% | -10.2% | -11.3% |
Recent Filings
8-K · 8.01
!! High
NeuroOne Medical Technologies Corporation -- 8-K 8.01: Material Event / Announcement
NeuroOne Medical Technologies regained Nasdaq compliance after its stock price recovered to $1.00 or higher for ten consecutive trading days, resolving delisting concerns.
May 4
8-K · 5.02
!!! Very High
NeuroOne Medical Technologies Corporation -- 8-K 5.02: Executive Change
NeuroOne Medical Technologies' CFO Ronald McClurg will retire June 30, 2026, creating potential leadership uncertainty during a critical financial oversight period.
Apr 30
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
NMTC executed a stock split with proportional adjustments to equity plans and outstanding options, potentially signaling management confidence but diluting per-share metrics that investors should recalibrate.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NMTC amended its 2025 equity plan without shareholder approval, potentially diluting shares and increasing management compensation flexibility, which could pressure stock performance if excessive.
Apr 3
8-K · 8.01
!! High
NeuroOne Medical Technologies Corporation -- 8-K 8.01: Material Event / Announcement
NeuroOne Medical Technologies set its 2026 annual shareholder meeting for April 3, 2026, with additional details forthcoming in the proxy statement.
Feb 25
8-K
NeuroOne Medical Technologies Corporation -- 8-K Filing
NeuroOne Medical Technologies reported Q1 FY2026 financial results and business updates, though specific metrics and outcomes require review of the complete filing for investor impact assessment.
Feb 17
Data updated apr 26, 2026 3:21pm
· Source: massive.com